海思科 (002653)

Haisco Pharmaceutical Group Co.,Ltd

ASZ

Tags

MSCI Component StocksGeneric DrugsInnovative DrugsChemical PharmaceuticalsInvestments in Financial InstitutionsFund Heavy PositionsVitaminsSME 300 IndexShenzhen ConnectSZSE 300 IndexTech 100 IndexPharma & BiotechSZSE Defensive 50 IndexSME Board Emerging IndexSZSE Medicine Equal Weight IndexPharmaceutical IndexZhongchuang Equal Weight IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexSZSE 1000 IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexSZSE Component Index ReturnLarge & Mid-cap IndexCNI 1000 IndexNew Virus PreventionHepatitis B VaccineAugust 2021 Lock-up ExpiryFTSE Russell ConceptHuijin ConceptJune 2022 Lock-up ExpiryTibet RevitalizationTibet ConceptJune 2021 Lock-up ExpiryPension Industry IndexSME Board Composite IndexSZSE Selected IndexCS High-end Manufacturing IndexZhongchuang 100 Return IndexSZSE Technology IndexSHS Innovative Drugs IndexSZSE ChiNext 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexJuchao Small-cap IndexCNI 300 IndexCCTV 500 IndexSZSE Private Enterprises IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexCSI All-share Pharmaceutical IndexSZSE Pharmaceutical 50 IndexSZSE 300 Equal Weight IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexSME Board Performance IndexCSI 700 IndexMid-small Cap IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexSZSE 200 Return IndexSZSE 200 IndexZhongchuang 400 IndexCS Innovative Drugs IndexESG 300 IndexCR New Momentum IndexJuchao Mid-cap IndexSZSE 500 IndexCSI 500 Growth Valuation IndexStrategic Emerging Industries 100 Index

K-Line Chart

No K-line data available

Company NameHaisco Pharmaceutical Group Co., Ltd.
Listing Date2012-01-17
Issue Price20RMB
Registered Capital111991.79710k RMB
Legal RepresentativePangke Yan
Registered AddressA-04-04, Industry-City Integration Demonstration Park, Naidong District, Shannan City, Tibet Autonomous Region
IndustryChemical Pharmaceuticals
Main BusinessR&D, production, and sales of chemical drug preparations and active pharmaceutical ingredients
Company ProfileHaisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'Haisco' or 'the Company') was founded in 2000. It is a diversified and specialized listed pharmaceutical group integrating new drug R&D, manufacturing, and sales. The Company's R&D capabilities rank among the top in the chemical pharmaceutical industry, holding the leading market share in the parenteral nutrition segment. It is a top-ranked producer of liver disease medications in China. The Company currently has over 2,200 employees, including 32 PhDs and 203 Master's degree holders. The Company was listed on the Shenzhen Stock Exchange A-share market on January 17, 2012. In 2018, it achieved sales revenue of RMB 3.427 billion and a net profit of RMB 333 million.

Stock Details

1. Key Indicators

  • Total Shares(W): 111991.80
  • Circulating A-Shares(W): 48323.82
  • Earnings Per Share(RMB): 0.2637
  • Net Assets Per Share(RMB): 3.7745
  • Operating Revenue(W RMB): 330013.60
  • Total Profit(W RMB): 33771.42
  • Net Profit Attributable to Parent(W RMB): 29530.07
  • Net Profit Growth Rate(%): -22.66
  • Weighted Return on Equity(%): 7.0800
  • Operating Cash Flow Per Share(RMB): 0.3480
  • Undistributed Profit Per Share(RMB): 1.5542
  • Capital Reserve Per Share(RMB): 0.8921

2. Main Business

The main business covers:

  • New drug research and development
  • Production and manufacturing
  • Promotion and marketing business

3. Company Basic Information

  • Company Name: Haisco Pharmaceutical Group Co., Ltd.
  • Listing Date: 2012-01-17
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 17 Sanxiang Avenue, Zedang Town, Shannan City, Tibet Autonomous Region
  • Website: www.haisco.com
  • Company Profile: The company's predecessor was Tibet Kangxin Pharmaceutical Co., Ltd., established on August 26, 2005; later, through a resolution of the shareholders' meeting on October 16, 2009, it was renamed Tibet Haisco Pharmaceutical Group Co., Ltd. on March 24, 2010. On August 3, 2010, the shareholders' meeting of Haisco Co., Ltd. passed a resolution to convert Haisco Co., Ltd. into Tibet Haisco Pharmaceutical Group Co., Ltd. with all shareholders as promoters, based on the audited net assets of 246,842,945.13 RMB as of June 30, 2010, converted into 190,000,000 shares (par value 1.00 RMB per share) at a ratio of 1:0.76972. The registered capital was 190 million RMB, and the remaining amount after conversion was included in "Capital Reserve - Capital Premium." All assets, liabilities, business, and personnel of Haisco Co., Ltd. were assumed by the newly established joint-stock company. Zhongrui Yuehua verified the promoters' capital contribution and issued the "Zhongrui Yuehua Yan Zi [2010] No. 198" "Capital Verification Report" on August 3, 2010, confirming that the company's registered capital had been fully paid. On August 23, 2010, the company completed the industrial and commercial registration at the Shannan District Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" with registration number 5422002000081.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China Europe Medical Health Hybrid Securities Investment Fund A Class Fund 2139.75 4.44
2 Hong Kong Securities Clearing Company Limited Northbound Capital 1806.01 3.75
3 ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund A Class Fund 1560.01 3.24
4 ChinaAMC Innovation Pharmaceutical Theme Hybrid Securities Investment Fund A Class Fund 1305.57 2.71
5 Fullgoal Precision Medical Flexible Allocation Hybrid Securities Investment Fund A Class Fund 806.97 1.68
6 ChinaAMC Medical Service Flexible Allocation Hybrid Securities Investment Fund A Class Fund 587.17 1.22
7 Fullgoal Pharmaceutical Innovation Equity Securities Investment Fund A Class Fund 550.09 1.14
8 E Fund Health Care Industry Hybrid Securities Investment Fund A Class Fund 468.80 0.97
9 ChinaAMC Daxin Flexible Allocation Hybrid Securities Investment Fund A Class Fund 409.24 0.85
10 ChinaAMC Medical Active Growth One-Year Holding Hybrid Securities Investment Fund A Class Fund 292.87 0.61

5. Concept Sectors

  • Vitamins
  • Generic Drugs
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Financial Participation
  • Heavy Fund Holdings
  • MSCI Constituent
  • Zhongchuang 100
  • Small and Medium 100
  • Shenzhen 300
  • Consumption 100
  • Small and Medium 300
  • Shenzhen Innovation
  • Innovation 100

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information